Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management
Year: 2026
Type: article
Abstract: Cardiovascular diseases (CVDs) remain the leading cause of death and disability worldwide, with atherosclerotic cardiovascular disease (ASCVD) accounting for the largest proportion. Vascular inflammation is a major driver of ASCVD, contributing to plaque formation, progression, and rupture and influencing myocardial repair after infarction. Conventional anti-inflammatory therapies are limited by systemic toxicity and insufficient drug accumulation at lesion sites, restricting their capacity for precise intervention. Nanomedicines can deliver therapeutics to lesion sites and release them in response to local stimuli, potentially reducing systemic toxicity and offering a promising approach to inflammation-targeted treatment of ASCVD. Existing studies have largely cataloged nanocarrier types or evaluated efficacy in isolated disease models but have not provided an integrated perspective on inflammation management across the full ASCVD continuum. This review discusses the role of nanomedicines in preventive plaque stabilization and post-interventional management, including recovery after myocardial infarction and prevention of in-stent restenosis. Preclinical studies indicate that nanomedicines can reduce atherosclerotic plaque size and infarct size and mitigate ischemia-reperfusion injury and stent intimal hyperplasia, potentially improving cardiovascular outcomes. Future work should prioritize mechanistic validation in clinically relevant models and artificial intelligence (AI)-assisted precision medicine to accelerate the safe clinical adoption of inflammation-targeted nanomedicines for CVDs.
Source: Soft Science
DOI: 10.20517/ss.2026.187
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Open Access status: hybrid
OpenAlex ID: W7236649542
